



Press Release

Code: 02/BCC/09

For Immediate Release

For further information, please contact:

Julian Abery, Biacore AB
Vice President, Head of
Pharmaceutical & Biotech Business Unit
+44 (0)1386 853949
+44 (0) 7808 900732 (mobile)
julian.abery@biacore.com

Scientific/Trade Press Enquiries:
Michelle Lerner, HCC De Facto Group
+44 (0) 207 496 3354
m.lerner@hccdefacto.com

BMS Joins Other Pharma Investing in Biacore®C for QC

Uppsala, Sweden, 7th August, 2002 Biacore International AB today announced that Bristol-Myers Squibb (BMS) is the latest major pharmaceutical company to invest in its Biacore®C system for rapid concentration analysis in drug development, manufacturing quality control (QC) and in-process control applications. Biacore C is the first system based on Surface Plasmon Resonance technology designed specifically for compliance with worldwide regulatory requirements.

Offering the combined benefits of real-time data analysis with state-of-the-art validation features, Biacore C addresses the pressure faced by drug companies to bring new products to market faster while maintaining strict compliance with Good Laboratory/Good Manufacturing Practice. The system has been shown to reduce time for biomolecular analysis while meeting the highest demands for accuracy, sensitivity and reproducibility.

“Biacore C has won strong market acceptance, and we are pleased with the interest we have received from companies including BMS, Boehringer Ingelheim and other major pharma,” said Julian Abery, Vice President and Head of the Pharmaceutical & Biotech Business unit at Biacore. “As with our other systems, Biacore C incorporates

the knowledge, experience and engineering skills of Biacore AB, which enables us to provide instrumentation that offers advantages in quality, reliability and throughput of data from the early stages of research to the strict regulatory environment of drug development and manufacturing.”

– Ends –

Cautionary Statement

This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

About Biacore

Biacore is a global market leader in Surface Plasmon Resonance (SPR) technology based systems with its own sales operations in the U.S., across Europe, Japan, Australia and New Zealand. A strong patent portfolio protects Biacore's SPR technology, which gives unique real-time insights into biomolecular interactions. Target groups for the Company's products consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies around the world. Biacore is focusing on drug discovery and development as its prime areas for future growth. The Company currently has seven systems on the market, the most important of which are: Biacore® S51 for applications downstream of high-throughput screening (HTS) including rapid characterization of HTS hits, and the comprehensive pre-clinical evaluation of lead compounds, and Biacore® 3000, which offers flexibility in key life science research and drug discovery applications upstream of HTS. The recently introduced Biacore® C is specifically designed for compliant concentration analysis of biopharmaceuticals in GLP/GMP applications. A new SPR array chip system, which will provide higher information content, is expected to reach the market in 2004.

Based in Uppsala, Sweden, the Company is listed on Stockholmsbörsen and Nasdaq in the U.S. In 2001 the Company had sales of SEK 544 million and an operating income of SEK 64 million.

Further information on Biacore can be found on the web: www.biacore.com

Address and phone:

*Biacore International AB
Rapsgatan 7, SE-754 50 Uppsala, SWEDEN
Phone: +46 (0)18-67 57 00 Fax: +46 (0)18-15 01 10
e-mail: info@biacore.com*